There were 499 press releases posted in the last 24 hours and 448,550 in the last 365 days.

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Prostatic Neoplasms, Date of authorisation: 24/05/2022, Revision: 1, Status: Authorised

Camcevi is a medicine used in adult men for the treatment of advanced prostate cancer that is ‘hormone-dependent’, meaning that it responds to treatments that lower the level of the hormone testosterone. Camcevi is also used in combination with radiotherapy to treat locally advanced hormone-dependent prostate cancer and high-risk localised prostate cancer (this means that the cancer is likely to spread beyond the prostate gland to nearby tissues and become ‘locally advanced’). 

Camcevi is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance but has a different formulation. The reference medicine for Camcevi is Eligard. Camcevi is available as a ready-to-use medicine in contrast with Eligard, which requires pre-mixing before it can be given to the patient.

The active substance in Camcevi is leuprorelin.